The knowledge of these molecular features, along with the clinical benefit observed with CDK4/6 inhibitors (CDK4/6i) in HR+/HER2−–BC, provide a rationale for targeting cell cycle regulators in patients with relapsed or metastatic disease that are generally considered incurable and for which additional effective therapies are needed. The gene discussed is CDK4; the disease is breast cancer.